pitchforks , page-10

Thank you,
I sincerely enjoy the research of some of the posters here on the ANP thread who do now not post as regularly as before, most likely due to the fact that the falling shareprice creates a tidal wave of criticism whereas fundamental strength of the company is unchanged, if anything, rather increased since the times prior to the phase 1 trial results.

Most researched posters do lean back, accumulate and await the news rather than engage in daily bickering about 0.1 pips of price changes.



As for where I see the price in a year, I would agree with some here that Mipomersen is a valid point of comparison in terms of milestone expectation I do have for the company.

The extension of our exclusive licensing arrangement for ATL1101 was a very positive landmark. In biotech, those extensions might aggrevate the short term traders but mean in general substantial support from the partner companies for our technology.
Current global tightness on loan capacities does not allow for extensions of questionable programs. In this context most pharmas only bet on the most promising technologies and drop others.


International attention towards antisense drug developments will eventually take ANP to an entirely different price range and it would certainly pay to be onboard while market ignores the outlook.


If ATL1103 concludes phase 3 trials in 2 years and finds itself in a similar position to where Mipomersen is now, I would see our shareprice between 50 and 80 cents, conservatively.


Personally, I expect news within this downtrend channel to surprise market and start a similar run on the stock as we had previously witnessed.